Claire Bewshea

University of Exeter - IBD Pharmacogenetics Group

SCHOLARLY PAPERS

3

DOWNLOADS

361

SSRN CITATIONS

1

CROSSREF CITATIONS

0

Scholarly Papers (3)

1.

COVID-19 Vaccine-Induced Antibody Responses are Impaired in IBD Patients Treated with Infliximab or Tofacitinib, but not Thiopurines, Ustekinumab or Vedolizumab

Number of pages: 35 Posted: 20 Dec 2021
Imperial College London - Department of Metabolism, Digestion and Reproduction, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - IBD Pharmacogenetics Group, Imperial College Healthcare NHS Trust - Department of Medicine & Integrated Care, Imperial College London - Department of Metabolism, Digestion and Reproduction, University of Edinburgh - Centre for Inflammation Research, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Surgery and Cancer, Hull University Teaching Hospitals NHS Trust - Department of Gastroenterology, King’s College London - School of Immunology and Microbial Sciences, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, King's College Hospital - Department of Gastroenterology, University of Cambridge - NIHR BioResource, Cambridge University Hospitals NHS Trust - Department of Gastroenterology, University of Cambridge - NIHR BioResource, Barts Health NHS Trust - Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust - Department of Gastroenterology, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Immunology and Inflammation, Imperial College London, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, St Marks Hospital and Academic Institute - Department of Gastroenterology, University of Edinburgh - Centre for Inflammation Research, Royal Devon and Exeter NHS Foundation Trust - Department of Gastroenterology, Imperial College London - Department of Metabolism, Digestion and Reproduction and affiliation not provided to SSRN
Downloads 245 (228,823)

Abstract:

Loading...

SARS-CoV-2, immune-mediated inflammatory diseases, Inflammatory bowel disease, thiopurine, azathioprine, anti-TNF therapy, infliximab, vedolizumab, ustekinumab, tofacitinib, immunosuppressant, vaccine, ChAdOx1 nCoV-19, BNT162b2

2.

Neutralising Antibody Potency Against SARS-CoV-2 Ancestral and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease after Three Doses of COVID-19 Vaccine: A Prospective Multicentre Cohort Study (CLARITY)

Number of pages: 40 Posted: 21 Sep 2022
Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - IBD Pharmacogenetics Group, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, affiliation not provided to SSRN, Newcastle University, Government of the United Kingdom - Department of Gastroenterology, Barts Health NHS Trust - Department of Gastroenterology, NHS Lothian - Department of Gastroenterology, Imperial College London - Department of Immunology and Inflammation, St Marks Hospital and Academic Institute - Department of Gastroenterology, Imperial College London, Imperial College London - Department of Infectious Disease, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Royal Devon and Exeter NHS Foundation Trust - Department of Gastroenterology and Imperial College London - Department of Metabolism, Digestion and Reproduction
Downloads 84 (539,593)

Abstract:

Loading...

SARS-CoV-2, immune-mediated inflammatory diseases, inflammatory bowel disease, thiopurine, azathioprine, anti-TNF therapy, infliximab, vedolizumab, immunosuppressant, vaccine, ChAdOx1 nCoV-19, BNT162b2, mRNA1273, breakthrough infection, Omicron, BA.4/5

3.

COVID-19 Vaccine-Induced Antibody and T Cell Responses in Immunosuppressed Patients with Inflammatory Bowel Disease After the Third Vaccine Dose

Number of pages: 37 Posted: 25 Jul 2022
Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - IBD Pharmacogenetics Group, Imperial College Healthcare NHS Trust - Department of Medicine & Integrated Care, Imperial College London - Department of Metabolism, Digestion and Reproduction, University of Edinburgh - Centre for Inflammation Research, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Surgery and Cancer, Government of the United Kingdom - Department of Gastroenterology, Guy’s and St. Thomas NHS Foundation Trust - Department of Gastroenterology, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, King's College Hospital - Department of Gastroenterology, University of Cambridge - NIHR BioResource, University of Cambridge - NIHR BioResource, Barts Health NHS Trust - Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust - Department of Gastroenterology, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Immunology and Inflammation, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, St Marks Hospital and Academic Institute - Department of Gastroenterology, NHS Lothian - Department of Gastroenterology, Imperial College London, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Royal Devon and Exeter NHS Foundation Trust - Department of Gastroenterology, Imperial College London - Department of Metabolism, Digestion and Reproduction and Independent
Downloads 32 (833,272)
Citation 4

Abstract:

Loading...

SARS-CoV-2, immune-mediated inflammatory diseases, inflammatory bowel disease, thiopurine, azathioprine, anti-TNF therapy, infliximab, vedolizumab, ustekinumab, tofacitinib, immunosuppressant, vaccine, ChAdOx1 nCoV-19, BNT162b2, mRNA1273